## RECEIVED CENTRAL FAX CENTER

**-0**7/16/2007 11:23 2124860323

.

JUL 1 6 2007

PAGE 01/03

Docket No. CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) 836.047 Applicant(s): Murray, et al. Group Art Unit Examiner Filing Date Application No. 1617 Kantamnei, Shoba 06/28/2000 09/485,267 Invention: Use of CHolinesterase Inhibitors for Treating Attention Deficit Disorders **Election of Species** I hereby certify that this (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 571 273-8300) July 16, 2007 OΠ (Date) Tuvia Rotberg (Typed or Printed Name of Person Signing Cartificate) (Signature) Note: Each paper must have its own certificate of mailing.

JUL 1 6 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Murray, et al.

Serial No. 09/485,267 Filed: 06/28/2000

Examiner: Kantamneni, Shoba

Art Unit: 1617

For: Use of Cholinesterase Inhibitors for

**Treating Attention Deficit Disorders** 

Attorney Docket: 836.047

July 16, 2007

## VIA FAX (571) 273-8300

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## **ELECTION OF SPECIES PURSUANT TO 37 CFR 1.499**

Sir:

In response to the restriction requirement made in the above-captioned patent application mailed on June 20, 2007, Applicant elects Group I with traverse. Applicant traverses the restriction requirement on the grounds that the compounds in which X=-O- and those in which X=-NH- share a common skeleton and have a common cholinesterase functionality whereby both groups of compounds are suitable for combating attention deficit disorders.

In light of the above, Applicant respectfully requests that the Examiner withdraw his holding of lack of unity.

Respectfully submitted,

Tuvia Rotberg, (58,167)

LEVISOHN BEGER LLP
61 Broadway, 32<sup>nd</sup> Floor
New York, NY 10006
P (212) 386-7272 F (212) 486-0323
Customer No.: 04617